RIGL vs XRAY · P/E 9.1, rev $137.5M vs rev $1.78B
Rigel Pharmaceuticals Inc (RIGL) versus Dentsply Sirona Inc (XRAY) — a side-by-side from cached financials, not a winner call.
Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on US.
Dentsply Sirona Inc (XRAY) is a medical instruments & supplies company listed on NASDAQ.
Latest reported RIGL revenue for 2026-06-30 was $137.5M. Net income was $25.9M. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.
Latest reported XRAY revenue for 2026-06-30 was $1.78B. Net income was $27.0M. XRAY currently screens at market cap $2.01B.
RIGL currently screens at market cap $338.3M and trailing P/E 9.1. XRAY currently screens at market cap $2.01B.
Not investment advice. Open the RIGL and XRAY stock pages for the full models.
Not investment advice.